Home Cart Sign in  
Chemical Structure| 266359-83-5 Chemical Structure| 266359-83-5

Structure of Reparixin
CAS No.: 266359-83-5

Chemical Structure| 266359-83-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Reparixin is a non-competitive allosteric inhibitor of CXCR1 and CXCR2 activation, with IC50s of 1 nM and 100 nM, respectively.

Synonyms: Repertaxin; DF 1681Y

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Reparixin

CAS No. :266359-83-5
Formula : C14H21NO3S
M.W : 283.39
SMILES Code : O=C(NS(=O)(C)=O)[C@H](C)C1=CC=C(CC(C)C)C=C1
Synonyms :
Repertaxin; DF 1681Y
MDL No. :MFCD18633292
InChI Key :KQDRVXQXKZXMHP-LLVKDONJSA-N
Pubchem ID :9838712

Safety of Reparixin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Reparixin

GPCR

Isoform Comparison

Biological Activity

Target
  • CXCR1

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01220856 Pancreatic Islet Transplantati... More >>on in Type 1 Diabetes Mellitus Less << PHASE2 COMPLETED 2013-04-30 University Hospital Carl Gusta... More >>v Carus Dresden, Dresden, 01307, Germany|Ospedale San Raffaele, Milan, 20132, Italy Less <<
NCT01861054 Breast Cancer PHASE2 TERMINATED 2016-03-01 Indiana University Simon Cance... More >>r Center, Indianapolis, Indiana, 46202-5289, United States|University of Kansas Cancer Center, 4350 Shawnee Mission Pkwy, Suite 1500, Mailstop 6004, Fairway, Kansas, 66205, United States|The Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|Montefiore Medical Center, MMC Medical Park at Eastchester, Bronx, New York, 10461, United States|Weill Cornell Medical College, New York, New York, 10065, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Magee-Womens Hospital, Pittsburgh, Pennsylvania, 15213, United States|Sara Cannon Research Institute, Nashville, Tennessee, 37203, United States|The Methodist Hospital Research Institute, Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.53mL

0.71mL

0.35mL

17.64mL

3.53mL

1.76mL

35.29mL

7.06mL

3.53mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories